フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
IPA's Subsidiary BioStrand Secures Second VLAIO Research GrantIPA subsidiary BioStrand receives grant to expand LENSai platform by linking...
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics...
IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with...
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from...
IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03 In vivo, IND enabling evaluations of PolyTope®...
Traitement potentiel de la maladie de Parkinson et d'autres affections neurodégénératives IMMUNOPRECISE ANTIBODIES LTD. (la "Société" ou "IPA...
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's...
Potential to Treat Parkinson’s and Other Neurodegenerative Diseases IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX...
L'anticorps bloque l'interaction de liaison DFR/ACE2 par le biais d'un mécanisme d'action alternatif L'anticorps se lie à tous les variants...
Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action Binds to all tested variants of concern, likely...
ImmunoPrecise et Genmab conviennent d'un partenariat technologique axé sur les maladies infectieuses ImmunoPrecise et Litevax font progresser le...
ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease ImmunoPrecise and Litevax advance SARS-CoV-2 vaccine...
Le criblage soutient les approches potentielles pour le traitement de variants émergents et futurs du SARS-CoV-2 grâce à une thérapie combinée...
The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination...
La direction fera le point sur les nouveaux variants du SRAS-CoV-2 qui suscitent de l'inquiétude (Royaume-Uni, Afrique du Sud et...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約